Skip to main content

Table 1 Demographics and Outcomes

From: Venous thromboembolic disease in admitted blunt trauma patients: what matters?

Variable

VTE (n = 177)

No VTE (n = 10,749)

P

Age (years, median, IQR)

62 [48–79]

67 [45–82]

0.32

Male Sex

67.8%

53.0%

0.0001

Two or more comorbidities

50.3%

52.4%

0.63

Anticoagulant

10.2%

11.5%

0.65

Antiplatelet

10.7%

7.6%

0.16

Anticoagulant + Antiplatelet

18.6%

18.2%

0.97

Disseminated cancer and/or receiving chemotherapy

3.4%

1.1%

0.002

Motor vehicle crash + motorcycle crash

13.6%+22.6%

17.5%+5.5%

0.0005

Fall

49.7%

61.8%

0.003

Other

14.9%

15.1%

0.96

Body Mass Index$ (median, IQR)

28.4 [24.6–32.0]

26.2 [23.3–29.8]

< 0.0001

Injury Severity Score

16 [9-27]

9 [5-14]

< 0.0001

Abdomen Abbreviated Injury Score (AIS)  3

12.4%

4.5%

< 0.0001

Head/neck AIS  3

39.0%

22.3%

< 0.0001

Face AIS  3

1.1%

0.2%

0.07

Chest AIS  3

29.9%

17.0%

< 0.0001

Extremity AIS  3

50.3%

25.7%

< 0.0001

External AIS  3

0.6%

0.1%

0.18

Surgery in Operating Room (%)$$

87.6%

45.2%

< 0.0001

Inferior Vena Cava filter (%)

35.0%

0.15%

< 0.0001

Central line/Peripherally inserted central catheter (%)

32.8%

5.1%

< 0.0001

Mechanical Ventilation (%)

47.4%

9.9%

< 0.0001

Intensive Care Unit stay (%)

68.9%

27.0%

< 0.0001

Hosp LOS (days, median, IQR)

21 [14–36]

6 [4-10]

< 0.0001

Intensive Care Unit LOS (days, median, IQR)

14 [7-22]

0 [0–2]

< 0.0001

Non-VTE complications (%)

45.2%

8.2%

< 0.0001

Mortality (%)

6.8%

2.8%

0.004

Chemoprophylaxis (%)*

   

None

41.8%

24.7%

< 0.0001

subcutaneous heparin

42.9%

54.9%

0.002

prophylactic enoxaparin

13.5%

18.4%

0.12

coumadin

0.56%

0.8%

0.52

miscellaneous

1.1%

0.6%

1

VTE Location (%)

   

Infrageniculate only

13.0%

n/a

n/a

Suprageniculate only

22.6%

n/a

n/a

Infrageniculate + suprageniculate

24.9%

n/a

n/a

Lower extremity NFS

0.56%

n/a

n/a

Upper extremity

5.6%

n/a

n/a

Upper extremity + infrageniculate + suprageniculate

0.56%

n/a

n/a

PE only

24.9%

n/a

n/a

PE + infrageniculate

2.2%

n/a

n/a

PE + suprageniculate

1.1%

n/a

n/a

PE + infrageniculate + suprageniculate

3.9%

n/a

n/a

PE + upper extremity

0.56%

n/a

n/a

Days from admission to index VTE (median, IQR)

6 [3-11]

n/a

n/a

1 day from admission to index VTE

7.3%

n/a

n/a

  1. $11 VTE and 1233 No VTE patients had no BMI available
  2. $$Surgery in operating room indicates any surgical procedure other than IVC filter
  3. *Chemoprophylaxis for VTE patients indicates: (1) agent administered at least 1 day prior to VTE event; (2) of 76 VTE patients on heparin, 13 received a combination of sq heparin followed by enoxaparin on the day prior to the VTE; (3) miscellaneous category consists of heparin drip in 2 patients. For no VTE patients, chemoprophylaxis indicates: (1) index agent utilized following admission; (2) the miscellaneous category includes 49 patients who received Factor Xa inhibitors, 49 patients who received direct thrombin inhibitors, fondaparinux, and others